Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers
News
Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients whose ... Read more